Go or no go? Roche, Lilly and Teva await big regulatory readouts
September promises at least eight notable US marketing decisions, including a crucial lung cancer ruling for Roche’s Tecentriq and verdicts on Lilly and Teva’s competing…
September promises at least eight notable US marketing decisions, including a crucial lung cancer ruling for Roche’s Tecentriq and verdicts on Lilly and Teva’s competing…